![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200096 "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200124LOGO "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
Novo Nordisk: Make-And-Take Strategy For The Obesity Drug Market (NYSE:NVO) | Seeking Alpha
How to Use the Saxenda® (liraglutide) Injection 3 mg Pen
Saxenda: profiling the first NHS weight loss drug for a decade - Pharmaceutical Technology
Saxenda approved in Europe for the treatment of obesity
Saxenda® (liraglutide) Injection 3 mg Official Physician Site
Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg
![Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management](http://photos.prnewswire.com/prnfull/20141224/166096 "Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management")
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
Saxenda Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Novo Nordisk drags competitor to court over Saxenda copies — MedWatch
Effective obesity management: It's more than reducing numbers on the scale
Novo Nordisk: Saxenda Sales Flattening Out (NYSE:NVO) | Seeking Alpha
Saxenda Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Treatment with Saxenda reduced the risk of developing T2D
Can Novo Nordisk's pipeline transform obesity treatment? | pharmaphorum
FDA Approves Novo Nordisk's Saxenda as a Treatment for Chronic Weight Management
Saxenda | Weight Loss Injection | Pen | UK | PrivateDoc®
